PASCOE-Agil HOM-Injektopas in the Treatment of Rheumatic Disorders (157)

Pascoe Natural Healthcare

Status: Completed

Conditions: Arthralgia; Myalgias/Myopathy; Lumbago; Rheumatic Diseases

Study type: Observational

Funder types: Industry

Identifiers

NCT00922428

157 A 07 PA

Details and patient eligibility

About

The purpose of this observational study is to give an overview of the use of PASCOE-Agil HOM-Injektopas in a 2-4 week treatment of rheumatic disorders.

Full description

The purpose of this observational study is to give an overview of the use of PASCOE-Agil HOM-Injektopas in a 2-4 week treatment of rheumatic disorders of different aetiology and localisation, displaying a variety of symptoms.

Efficacy and tolerability of the drug will be assessed. Special regard will be taken to the administration management in relation to the Summary of Product Characteristics (SmPC).

Enrollment: 1,389 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Due to the design as an Observational Study no inclusion or exclusion criteria for therapy are named. The included patient group is described under "Cohort / Group".

Observational Criteria (=inclusion criteria for documentation):

• Males and females
• At least 18 years old
• Rheumatic disease with accompanying symptoms, e.g. arthralgia, myalgia, lumbago etc.

Exclusion criteria for documentation:

• younger than 18 years
• no Rheumatic disease with accompanying symptoms, e.g. arthralgia, myalgia, lumbago etc.
• no treatment with PASCOE-Agil HOM-Injektopas

Trial design

1,389 participants in 1 patient group

Observational group

Description:

Patients suffering from rheumatic disorders of different types and origins, especially those with arthralgia, myalgia, lumbago, or other diagnoses.